Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Shares Rose 33.7% in May

By Adria Cimino – Updated Jun 3, 2020 at 9:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive data from a coronavirus vaccine trial drove share gains.

What happened

Shares of Moderna (MRNA -0.55%) climbed 33.7% in May, according to data provided by S&P Global Market Intelligence, after the company reported encouraging data from its investigational coronavirus vaccine's phase 1 trial.

A researcher injects a globe with vaccine.

Image source: Getty Images.

Across all participants in two dosage groups, Moderna said, levels of binding antibodies were at or above levels seen in people who have recovered from the virus. Information on neutralizing antibodies (those that block infection) were only available for eight people. In those participants, neutralizing antibodies were also at or above levels found in recovered coronavirus patients.

Later in the month, Moderna announced the dosing of the first participants in its phase 2 trial. The company aims to start a phase 3 trial in July.

So what

Moderna was the first to start human trials and among the first to release results. Since there isn't an approved treatment or cure for the coronavirus, the world is eager for a vaccine. As a result, all eyes are on Moderna, which seems closest to the finish line. That said, the initial data released involves a limited number of participants in a young patient group (ages 18 to 55), and anything can happen in this ongoing trial as well as in later-stage trials.

Moderna also faces competition. The biotech is among 10 companies and research institutions that have brought a vaccine candidate into human trials. That said, there is likely room for more than one vaccine to serve worldwide demand.

The trials also are significant because the coronavirus vaccine, if approved, would be Moderna's first marketed product. The vaccine harnesses the power of messenger RNA to instruct the body to produce therapeutic proteins. Moderna uses this technology throughout its other programs, so positive data here may indicate the method could work in other diseases.

Now what

Investors should watch for more data from the ongoing phase 1 trial as well as data from the phase 2 trial, which will involve 600 participants in two age groups. Safety and immune response in older adults, who are most affected by the coronavirus, will be key, as will the production of neutralizing antibodies.

Like peers working on a coronavirus vaccine, Moderna may see its stock price soar on positive data, while a setback for the project would likely be a setback for the shares as well.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$123.64 (-0.55%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.